Northeast Financial Consultants’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $74.4K | Hold |
93,000
| – | – | ﹤0.01% | 294 |
|
|
2025
Q1 | $85.4K | Hold |
93,000
| – | – | ﹤0.01% | 273 |
|
|
2024
Q4 | $88.4K | Hold |
93,000
| – | – | ﹤0.01% | 282 |
|
|
2024
Q3 | $118K | Hold |
93,000
| – | – | 0.01% | 284 |
|
|
2024
Q2 | $121K | Hold |
93,000
| – | – | 0.01% | 263 |
|
|
2024
Q1 | $142K | Hold |
93,000
| – | – | 0.01% | 281 |
|
|
2023
Q4 | $109K | Buy |
93,000
+10,000
| +12% | +$11.7K | 0.01% | 272 |
|
|
2023
Q3 | $72.2K | Hold |
83,000
| – | – | ﹤0.01% | 279 |
|
|
2023
Q2 | $93K | Hold |
83,000
| – | – | 0.01% | 281 |
|
|
2023
Q1 | $86.3K | Hold |
83,000
| – | – | 0.01% | 306 |
|
|
2022
Q4 | $93K | Buy |
83,000
+30,000
| +57% | +$33.6K | 0.01% | 310 |
|
|
2022
Q3 | $60K | Hold |
53,000
| – | – | ﹤0.01% | 328 |
|
|
2022
Q2 | $78K | Hold |
53,000
| – | – | 0.01% | 320 |
|
|
2022
Q1 | $121K | Hold |
53,000
| – | – | 0.01% | 375 |
|
|
2021
Q4 | $146K | Buy |
53,000
+40,000
| +308% | +$110K | 0.01% | 342 |
|
|
2021
Q3 | $78K | Buy |
13,000
+3,000
| +30% | +$18K | 0.01% | 347 |
|
|
2021
Q2 | $49K | Hold |
10,000
| – | – | ﹤0.01% | 344 |
|
|
2021
Q1 | $25K | Buy |
+10,000
| New | +$25K | ﹤0.01% | 328 |
|